Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $6.25, for a total value of $104,168.75. Following the sale, the insider directly owned 1,226,507 shares of the company’s stock, valued at approximately $7,665,668.75. This represents a 1.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Beth Hecht also recently made the following trade(s):

• On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.45, for a total value of $124,169.15.
• On Friday, January 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.43, for a total value of $123,835.81.

Xeris Biopharma Stock Performance

XERS traded up $0.01 during trading on Thursday, reaching $6.08. 1,012,351 shares of the company’s stock were exchanged, compared to its average volume of 2,069,536. The stock has a market capitalization of $1.05 billion, a P/E ratio of -607.39 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a 1 year low of $3.81 and a 1 year high of $10.08. The company’s fifty day simple moving average is $7.16 and its 200-day simple moving average is $7.61. The company has a debt-to-equity ratio of 16.10, a current ratio of 2.19 and a quick ratio of 1.35.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Monday, March 2nd. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. The company had revenue of $85.81 million for the quarter, compared to analyst estimates of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. As a group, research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after buying an additional 1,358,760 shares in the last quarter. Geode Capital Management LLC raised its position in Xeris Biopharma by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after purchasing an additional 135,815 shares during the last quarter. State Street Corp boosted its stake in Xeris Biopharma by 10.1% during the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after purchasing an additional 378,595 shares during the period. Qube Research & Technologies Ltd grew its position in Xeris Biopharma by 6.0% during the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after purchasing an additional 185,063 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating with a $10 price target and published multi‑year upside EPS forecasts through 2030, signalling confidence in the company’s longer‑term revenue progress and pipeline potential. HC Wainwright coverage / MarketBeat
• Positive Sentiment: Several third‑party pieces, including a bullish Seeking Alpha article, argue Xeris is undervalued relative to its drug portfolio, which can attract value and growth‑oriented investors. Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio
• Positive Sentiment: Analyst consensus has been summarized as a “Moderate Buy” by market coverage services, indicating general analyst support that can underpin momentum. Consensus Rating of Moderate Buy
• Neutral Sentiment: HC Wainwright published specific quarterly estimates (Q1‑Q4 2026) including a Q1‑2026 EPS estimate of ($0.03) and a FY2026 view of $0.06 — these provide a roadmap for expected near‑term results but include mixed signs as the company transitions to profitability horizons. HC Wainwright estimates / MarketBeat
• Neutral Sentiment: Consensus full‑year EPS remains negative (around ‑$0.41), so near‑term profitability is still a risk until guidance/actuals show consistent improvement. Consensus estimates / MarketBeat
• Negative Sentiment: An insider (Beth Hecht) sold 16,667 shares at an average $6.25 on Mar 2, which may be perceived negatively by some investors as a liquidity or confidence signal. SEC filing: Insider sale Form 4
• Negative Sentiment: HC Wainwright trimmed several mid‑/long‑range EPS forecasts (FY2026‑FY2029 revisions downward), which reduces near‑term upside expectations and could temper sentiment until revenue trends validate earlier, higher projections. HC Wainwright revisions / MarketBeat

Wall Street Analyst Weigh In

A number of research analysts have weighed in on XERS shares. Oppenheimer reiterated an “outperform” rating and issued a $18.00 price objective on shares of Xeris Biopharma in a research report on Friday, November 7th. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Piper Sandler boosted their price target on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Barclays assumed coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a research report on Monday. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Xeris Biopharma has an average rating of “Moderate Buy” and a consensus price target of $10.08.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.